Our People

Meet our team, who bring a wealth of knowledge, experience and understanding to build trusted client relationships and accelerate the process of bringing life-changing drugs to market.

Meet the Team

At KCAS Bio, we firmly believe in the power of knowledge, collaboration, accountability, and service. It is through the unwavering dedication of our team that we strive to make a meaningful impact on patients' lives. Get to know the passionate minds driving our innovative solutions and discover how our brand values shape everything we do.

Podcast (The Weekly Bioanalysis) Eps #94: “Conference Season 2025: US, APAC, and European Bioanalysis Trade Shows” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #94: “Conference Season 2025: US, APAC, and European Bioanalysis Trade Shows”

In this episode, hosts Dom and John welcome Jason Hannah, Director of Marketing at KCAS Bio, to discuss the company’s strategy for navigating the 2025 global conference season. With major events like AAPS PharmSci 360 in the U.S. and the European Bioanalysis Forum (EBF) in Barcelona on the horizon, Jason…

Podcast (The Weekly Bioanalysis) Eps #93: “Collaborating with Agile, Scientific Partners to Accelerate Drug Development” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #93: “Collaborating with Agile, Scientific Partners to Accelerate Drug Development”

During episode #93 of The Weekly Bioanalysis, John and Dom welcome guest Chris Crean, founder/CEO of Xyzagen, who reflects on three decades in drug development and how the field has shifted from small molecules to today’s complex biologics, gene editing, and beyond. Chris explains how Xyzagen helps small, science-driven teams…

Podcast (The Weekly Bioanalysis) Eps #91: “The ‘Grey Areas’ of BioA: Drug Discovery, Biomarkers, Tissues & Technologies” Podcasts
Read article Podcast (The Weekly Bioanalysis) Eps #91: “The ‘Grey Areas’ of BioA: Drug Discovery, Biomarkers, Tissues & Technologies”

In episode #91 of The Weekly Bioanalysis, John and Dom return to a two-person format to tackle the “gray areas” of bioanalysis, focusing on drug discovery, biomarkers, tissues, and emerging technologies. They discuss how traditional PK assay validation is highly standardized, but areas like early-stage discovery, biomarker qualification, and tissue…

Tell us how we can help with your project

We've earned our reputation for delivering reliable, error-free data. We understand the importance of speed, flexibility, and consistency and only make promises we can keep.

Talk to an expert